Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
3
×
boston top stories
clinical trials
life sciences
national blog main
boston
drugs
national top stories
new york blog main
onpattro
patisiran
san diego blog main
acute hepatic porphyrias
akcea therapeutics
akin akinc
alnylam pharmaceuticals
aminolevulinic acid
anylam pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
cardiomyopathy
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
fda
gene therapy
givosiran
inotersen
joshua brumm
kaleido biosciences
muscular dystrophy
myotonic dystrophy type 1
neuropathy
new york
new york top stories
paul matteis
What
ago
3
×
drug
3
×
alnylam
fda
genetic
medicines
rare
akcea
amyloidosis
approval
approved
attr
available
battle
biotechs
considering
data
debilitating
disease
diseases
dyne
early
expected
experimental
eyes
having
humans
indicated
interference
ipo
ipos
long
medicine
muscle
nod
oks
patients
pfizer
pharmaceuticals
quick
Language
unset
Current search:
ago
×
" boston blog main "
×
drug
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug